Impact Factor
4.48
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
7.35
3,351 total citations
h5-index
64
h5 depth signal
Cited share
88.8%
437 of 492
Total citations
3,351
Citation footprint
Metric signal
8.16
External metric anchor
Self-citation
1.1%
36 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
741
China
585
United States
449
United Kingdom
208
France
193
Citing Fields of Research
Oncology
1,095
Immunology
592
Lung Cancer
305
Breast Cancer
274
Cancer & Development
254
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,056
Articles tracked across the journal lifetime
Indexed publication set
492
437 cited publications
Last 12 months
551
45.9 publications/month
Open access share
27.9%
154 OA publications in the last year
Leading citing country
Italy
741 citing publications
Leading citing field
Oncology
1,095 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1983-
v1n1, 1983-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Lung Cancer
Breast Cancer
Liver & Colon Cancer
Cancer, Autophagy & Apoptosis
Issuing & Sponsoring Bodies
Contributor
Chemical Rubber Company
Broad Categories
Hematology
Neoplasms
Immunology
Lung Cancer
Liver & Colon Cancer
Cancer, Autophagy & Apoptosis
Brain Imaging
Breast Cancer
MeSH Descriptors
Hematologic Diseases
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1016/j.critrevonc.2026.105652
Open DOI
Prognostic value of circulating tumor DNA in esophageal and gastric cancer by treatment stage: a systematic review and meta-analysis
03
04
DOI 10.1016/j.critrevonc.2026.105651
Open DOI
Survival by Design: Cell Fate Dynamics in Classical Hodgkin Lymphoma
05
DOI 10.1016/j.critrevonc.2026.105649
Open DOI
When is 4 Gy enough? Defining dose sufficiency and durable control in indolent B-cell lymphoma
06
DOI 10.1016/j.critrevonc.2026.105642
Open DOI
Rewiring the Tumor–Immune Ecosystem: Extracellular Vesicles in the Next Era of Cancer Immunotherapy
07
DOI 10.1016/j.critrevonc.2026.105647
Open DOI
Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy
08
DOI 10.1016/j.critrevonc.2026.105648
Open DOI
Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.
09
DOI 10.1016/j.critrevonc.2026.105643
Open DOI
Stromal-myeloid-lymphoid crosstalk in immune evasion and immunotherapy resistance in solid tumors
10
DOI 10.1016/j.critrevonc.2026.105644
Open DOI
Targeting adipose tissue-vascular crosstalk in tumor angiogenesis
Bibliographical & Catalog Notes
Place of publication varies.
Also issued online.
Vol. 1, no. 1 (1983)19911012 Notice not published Printed on acid-free paper